1. Introduction {#sec1-cancers-12-01444}
===============

The treatment outcome of acute promyelocytic leukemia (APL) has markedly improved over the past three decades following the development of novel agents including all-*trans* retinoic acid (ATRA), arsenic trioxide (ATO) and chemotherapy \[[@B1-cancers-12-01444],[@B2-cancers-12-01444],[@B3-cancers-12-01444],[@B4-cancers-12-01444],[@B5-cancers-12-01444],[@B6-cancers-12-01444],[@B7-cancers-12-01444]\]. Recently, 90% of patients with APL achieve complete remission (CR) after induction therapy, and 80% of patients maintain long-term, disease-free survival. However, several % of patients in the low-risk group and 10--20% of those in the high-risk group have a recurrence of the disease after the first remission \[[@B8-cancers-12-01444],[@B9-cancers-12-01444],[@B10-cancers-12-01444],[@B11-cancers-12-01444],[@B12-cancers-12-01444],[@B13-cancers-12-01444]\]. Treatment of patients in the high-risk group for APL has therefore been a major focus of attention in this area. Analyses of prognostic factors is still crucial in the management of APL.

Various prognostic factors with an expected outcome have been reported. Specifically, high white blood cell (WBC) count with or without low platelet count before the induction treatment have been recognized as significant factors \[[@B7-cancers-12-01444],[@B9-cancers-12-01444],[@B10-cancers-12-01444],[@B11-cancers-12-01444],[@B12-cancers-12-01444]\]. More detailed analyses have shown the relationship between a poor outcome and several characteristics, including older age, chromosomal abnormalities other than t (15;17), phenotypic features, FLT3 mutations and presence of the *PML-RARA* isoform \[[@B13-cancers-12-01444],[@B14-cancers-12-01444],[@B15-cancers-12-01444],[@B16-cancers-12-01444],[@B17-cancers-12-01444]\]. However, these observations have not received approval to amend the standard therapy for APL \[[@B18-cancers-12-01444],[@B19-cancers-12-01444],[@B20-cancers-12-01444]\].

Recently, we analyzed the long-term outcomes of the Japan Adult Leukemia Study Group (JALSG) APL 204 study, prospectively treated with ATRA combined with chemotherapies followed by maintenance therapy with ATRA or tamibarotene \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. Tamibarotene, a synthetic retinoid, is chemically more stable to light, heat and oxidation than ATRA, and is approximately 10 times more potent in its ability to induce in vitro differentiation \[[@B23-cancers-12-01444],[@B24-cancers-12-01444]\]. Tamibarotene displays a low affinity for cellular retinoic acid binding protein, the overexpression of which is associated with ATRA resistance. Moreover, unlike ATRA, the plasma level of tamibarotene does not decline after daily administration. We have shown that tamibarotene is superior to ATRA by decreasing the incidence of relapse \[[@B21-cancers-12-01444],[@B22-cancers-12-01444],[@B25-cancers-12-01444],[@B26-cancers-12-01444]\]. Additionally, we showed that a high WBC count at diagnosis is one of the significant prognostic factors for poor relapse-free survival (RFS) \[[@B22-cancers-12-01444]\]. Here, we precisely analyzed the data of the APL204 study at a median follow-up of 7.3 years. Our aim was to identify important prognostic factors in 344 APL patients enrolled in the study, of which 269 underwent maintenance randomization. Moreover, we compared these patients with 302 patients enrolled in our previous APL97 study (a median follow-up of 8.5 years) who underwent ATRA treatment and chemotherapy with or without intensive maintenance chemotherapy \[[@B7-cancers-12-01444],[@B27-cancers-12-01444]\].

2. Materials and Methods {#sec2-cancers-12-01444}
========================

2.1. Patients {#sec2dot1-cancers-12-01444}
-------------

Adult patients with previously untreated APL with t (15;17) and/or the *PML-RARA* were enrolled onto the JALSG-APL204 study between April 2004 and December 2011 \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. Other eligibility criteria included age between 15 and 70 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 3, and sufficient functioning of the heart, lung, liver and kidney. Written informed consent was obtained from each patient before registration to the study in accordance with the Declaration of Helsinki. This study was approved by the institutional review boards of each participating institution and registered at the University Hospital Medical Information Network Clinical Trials Registry under C000000154.

2.2. Treatments {#sec2dot2-cancers-12-01444}
---------------

The JALSG-APL204 is a randomized controlled, phase three multicenter study \[[@B21-cancers-12-01444]\]. An outline of the treatment schedule is reproduced in [Figure 1](#cancers-12-01444-f001){ref-type="fig"}. \[[@B22-cancers-12-01444]\] For remission induction therapy, ATRA (45 mg/m^2^/day) was given until complete remission (CR) for up to 60 days. In accordance with previous JALSG APL studies, simultaneous chemotherapy with idarubicin (IDA) and cytarabine (Ara-C) was given in accordance with the initial WBC and blast count in the peripheral blood \[[@B7-cancers-12-01444]\]. After achieving complete remission (CR), three courses of intensive consolidation chemotherapy including anthracyclines and Ara-C were given; in particular, mitoxantrone 7 mg/m^2^ on days one to three and Ara-C 200 mg/m^2^ on days one to five for the first course; daunorubicin 50 mg/m^2^ on days one to three and Ara-C 200 mg/m^2^ on days one to five for the second course; and IDA 12 mg/m^2^ on days one to three and Ara-C 140 mg/m^2^ on days one to five for the third course. Intrathecal injection (IT) was given after recovery from the second consolidation course as prophylaxis for central nervous system (CNS) leukemia. Patients, whose *PML-RARA* fusion transcripts were not found after consolidation, were randomly allocated either to ATRA (45 mg/m^2^/day) or tamibarotene (6 mg/m^2^/day) maintenance for 14 days every three months for up to two years.

CR and hematological relapse were defined to be consistent with previous reports \[[@B7-cancers-12-01444],[@B21-cancers-12-01444]\]. *PML-RARA* transcript levels were evaluated in bone barrow after recovery of the third consolidation therapy, and then after every two courses of maintenance therapy, and every six months thereafter. Transcript levels were determined using the real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) assay \[[@B7-cancers-12-01444],[@B21-cancers-12-01444]\]. Molecular remission was defined by *PML-RARA* transcript levels as being less than 100 copies/μg RNA. Molecular relapse was defined as a loss of molecular remission confirmed in two consecutive bone marrow samples taken at one-month intervals.

2.3. Immunophenotypic Analyses {#sec2dot3-cancers-12-01444}
------------------------------

Immunophenotypic analyses were performed using bone marrow samples at diagnosis by flow cytometry. Cells were stained with anti-CD45 monoclonal antibody (mAb), gated by CD45 expression and side scatter (SSC), and analyzed by fluorescein conjugated mAb against CD2, CD5, CD7, CD4, CD8, CD19, CD20, CD11b, CD13, CD14, CD15, CD33, CD34, CD56 and HLA-DR antigens. In accordance with the EGIL criteria \[[@B28-cancers-12-01444]\], surface markers generally not determined on APL cells were defined as positive if more than 10% of APL cells expressed the corresponding antigens.

2.4. Definition of Outcomes {#sec2dot4-cancers-12-01444}
---------------------------

Relapse-free survival (RFS) was defined as the time from random assignment to hematological or molecular relapse, death or last visit, whichever came first. Overall survival (OS), event-free survival (EFS), cumulative incidence of relapse (CIR), RFS in the initial treatment groups and RFS in risk groups were also analyzed using standard definitions as described in our previous paper \[[@B7-cancers-12-01444]\].

2.5. Statistical Analysis {#sec2dot5-cancers-12-01444}
-------------------------

Long-term survival, disease status and late complications at 7.3 years were collected between January 2016 and June 2018. Categorical data were compared using χ^2^-test and Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. The probabilities of RFS, OS and EFS were estimated using the Kaplan--Meier method. CIR was analyzed by Gray's test \[[@B29-cancers-12-01444]\]. The Cox proportional hazards regression model was used for calculating the hazard ratio (HR) in conjunction with the 95% confidence interval (CI). Factors significant at the 0.2 level in the univariate analysis were included in the multivariate analysis model. Statistical analyses were performed using SPSS 25.0 (SPSS Inc, Chicago, IL, USA) and EZR 1.37, a graphical user interface for the R software program (The R Foundation for Statistical Computing, Vienna, Austria). All hypothesis testing was two-tailed with a significance level of 0.05.

3. Results {#sec3-cancers-12-01444}
==========

3.1. Patient Characteristics {#sec3dot1-cancers-12-01444}
----------------------------

Between April 2004 and December 2010, 347 newly diagnosed patients with APL were enrolled for this study, of which 344 were eligible for analysis \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. The median follow-up period was 7.3 years (0 to 12.3 years). [Table 1](#cancers-12-01444-t001){ref-type="table"} shows the baseline characteristics of the eligible patients. Among them, 325 (94%) (median age, 48 years; range, 15 to 70) had satisfactory data of the CD phenotype and were evaluated in this study.

3.2. Treatment Outcome {#sec3dot2-cancers-12-01444}
----------------------

Of the 344 eligible patients, 319 (93%) achieved CR. After completing consolidation chemotherapy, 269 patients underwent maintenance random assignment; 135 were given ATRA, and 134 were given tamibarotene. A CONSORT diagram is summarized and reproduced in [Figure 2](#cancers-12-01444-f002){ref-type="fig"}. \[[@B22-cancers-12-01444]\] Results from univariate analysis of risk factors for CR are given in [Table 2](#cancers-12-01444-t002){ref-type="table"}. Patients with initial WBC counts of 3.0 × 10^9^/L or more had a lower CR rate compared to those with initial WBC counts of less than 3.0 × 10^9^/L (*p* = 0.011). Overexpression of CD phenotypes CD34 and CD56 in relation to CR rate were also analyzed (*p* = 0.417 and *p* = 0.212, respectively). Death within 30 days was compared with clinical features and reported elsewhere. In brief, the mortality rate increased in patients with initial WBC counts of 3.0 × 10^9^/L or more (*p* = 0.002), platelet counts of less than 40.0 × 10^9^/L (*p* = 0.026) and those with variant FAB subtype (*p* = 0.031) and a higher Sanz score (*p* = 0.008). Three of 344 patients had refractoriness to the induction. The incidence of differentiation syndrome did not relate to any of the clinical features.

[Table 3](#cancers-12-01444-t003){ref-type="table"}a summarizes the results from univariate analysis on RFS, which is the primary endpoint of this study. Univariate regression analysis found several risk factors for adverse prognosis including initial WBC count (≥10.0 × 10^9^/L) (*p* \< 0.001), Sanz score (*p* = 0.001), CD34^+^ (*p* = 0.040), CD56^+^ blast (≥10%) (*p* = 0.005) and the ATRA arm in maintenance therapy (*p* = 0.027). By contrast, age, sex, PS, and chromosome abnormality other than t (15; 17) were not significant factors. The unique factors found to be significant in univariate regression analysis were included in the multivariate analysis of risk factors for adverse prognosis ([Table 3](#cancers-12-01444-t003){ref-type="table"}b). Consequently, overexpression of CD56 in blast was an independent unfavorable prognostic factor for RFS (HR = 3.19, 95% CI 1.40--7.27, *p* = 0.006) together with a WBC count of more than 10.0 × 10^9^/L (*p* = 0.001) and the ATRA arm in maintenance therapy (*p* = 0.028). The latter two factors were reported in our previous report on the primary endpoint \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. The relationships between CD phenotypes and clinical outcomes are summarized in [Table 4](#cancers-12-01444-t004){ref-type="table"}. Of all CD phenotypes, CD56 was related most clearly to adverse prognosis. Therefore, we focused on the clinical impact of CD56 on treatment outcome in relation to other prognostic factors.

Of the 325 patients that were analyzable, 45 (13.8%) were positive for CD56. The clinical and biological characteristics according to CD56 expression are shown in [Table 5](#cancers-12-01444-t005){ref-type="table"}. CD56 expression was not related to any of these characteristics. As for the relationship of CD56 with other CD phenotypes, a significant correlation was found with each of CD2, CD7, CD34, HLA-DR (*p* \< 0.001, each), but not with each of CD11b and CD15 (*p* = 0.096 and *p* = 0.339, respectively). However, none of these except CD56 related to clinical outcome in the multivariate analysis.

EFS, RFS and CIR were inferior in CD56^+^ APL (66.1% vs. 83.1%, *p* = 0.007, 76.5% vs. 91.4%, *p* = 0.005, HR 3.04 (1.34--6.90) and 23.5% vs. 8.1%, *p* = 0.004, HR 3.34 (1.45--7.69, respectively) than for CD56^−^ APL, while OS was not significantly different between the two groups (78.9% vs. 89.4%, *p* = 0.069) ([Figure 3](#cancers-12-01444-f003){ref-type="fig"}). In patients with initial WBC counts of 3.0 × 10^9^/L or more, RFS and CIR for 14 CD56^+^APL patients were significantly inferior to those for 67 CD56^−^APL patients (64.3% vs. 86.6%, *p* = 0.028, and 35.7% vs. 13.4%, *p* = 0.036, respectively; [Figure 4](#cancers-12-01444-f004){ref-type="fig"}), while in patients with initial WBC counts of less than 3.0 × 10^9^/L, RFS and CIR were not significantly different between the two groups (*p* = 0.164 and *p* = 0.101, respectively). In a limited number of patients, OS was not significantly different between the two groups regardless of the initial WBC count. RFS and CIR for 8 CD56^+^APL patients among those with initial WBC counts of 10.0 × 10^9^/L or more were not significantly different from those for 43 CD56^−^APL patients (62.5% vs. 79.1%, *p* = 0.200, and 20.9% vs. 37.5%, *p* = 0.220, respectively). We also analyzed the influence of CD56 expression on clinical outcomes according to Sanz's relapse-risk score \[[@B4-cancers-12-01444]\]. OS, EFS, RFS, and CIR were not significantly different between CD56^−^ and CD56^+^ patients in the high-risk group. Among 221 CD56^−^ patients, RFS in patients treated with tamibarotene was significantly better than that with ATRA (*p* = 0.001), but not in 34 CD56^+^ patients (*p* = 0.359). These observations might be explained by the small number of CD56^+^ cases in the high-risk group. Therefore, we analyzed the differences in the high- and intermediate-risk groups together. The RFS and CIR were significantly inferior in 26 CD56^+^ patients (76.5% vs. 90.4%, *p* = 0.039 and 23.1% vs. 9.5%, *p* = 0.037, respectively), while OS and EFS were unchanged (*p* = 0.202 and *p* = 0.082).

In addition, we analyzed the outcome of CD34^−^CD56^−^ (177 cases), CD34^+^CD56^−^ (44 cases), CD34^−^CD56^+^ (13 cases) and CD34^+^CD56^+^ (21 cases) groups. RFS of these were 92.5%, 85.9%, 76.9% and 75.6%, respectively. (CD34^−^CD56^−^ vs. CD34^+^CD56^−^, *p* = 0.083; CD34^−^CD56^−^ vs. CD34^−^CD56^+^, *p* = 0.019; and CD34^−^CD56^−^ vs. CD34^+^CD56^+^, *p* = 0.010).

4. Discussion {#sec4-cancers-12-01444}
=============

We recently reported that tamibarotene maintenance improved RFS of APL in our JALSG-APL204 study with a median follow-up of 7.3 years (HR = 0.44, 95%CI 0.21-0.93, *p* = 0.027) \[[@B22-cancers-12-01444]\]. This observation was more pronounced in high-risk patients with an initial leukocyte count of ≥10.0 × 10^9^/L (HR = 0.27, 0.07--0.99, *p* = 0.034). We further evaluated other important prognostic factors with multivariate analysis. In particular, immunophenotypes were extracted during this evaluation.

The relationships between immunophenotypes and clinical outcome have been reported in AML. Of all immunophenotypes, overexpression of CD56 has been reported in 15% to 20% of AML patients with poorer survival \[[@B30-cancers-12-01444],[@B31-cancers-12-01444]\]. This observation has been reported in several AML subtypes having *RUNX1-RUNX1T1* or *PML-RARA* \[[@B14-cancers-12-01444],[@B30-cancers-12-01444],[@B31-cancers-12-01444]\] and is thought to be related to hyperleukocytosis or extramedullary involvement \[[@B32-cancers-12-01444],[@B33-cancers-12-01444],[@B34-cancers-12-01444]\]. These findings indicate that CD56 is related to the progression of AML and resistance to therapy.

Previous reports have suggested that overexpression of CD2, CD34, HLA-DR and CD56 in APL patients is associated with poorer clinical outcomes \[[@B14-cancers-12-01444],[@B27-cancers-12-01444],[@B35-cancers-12-01444],[@B36-cancers-12-01444],[@B37-cancers-12-01444],[@B38-cancers-12-01444]\]. Our study indicates CD2, CD7, CD34 and CD56 are associated with a poorer clinical outcome, and CD56 was extracted in multivariate analysis. CD56 is expressed in around 10% of patients with APL \[[@B39-cancers-12-01444],[@B40-cancers-12-01444],[@B41-cancers-12-01444],[@B42-cancers-12-01444]\]. Our previous report on long-term survival of APL97, which analyzed 239 patients with APL, also highlighted the prognostic significance of CD56 expression \[[@B27-cancers-12-01444]\]. The study showed CD56 expression was correlated with lower platelet counts and severe intravascular coagulation before induction therapy, but not with higher WBC counts, lower albumin levels and higher frequency of M3 variant, as reported previously \[[@B39-cancers-12-01444],[@B41-cancers-12-01444]\]. Indeed, in the analysis of APL204, overexpression of CD56 was not correlated with any of these clinical features before induction therapy. This observation suggests that long-term outcomes in APL204 were improved by comparison to those in APL97. Prognostic factors are often difficult to extract in a developed regimen.

There was no difference in each of CR and induction mortality between the CD56^+^ and CD56^−^ groups in our study \[[@B27-cancers-12-01444]\]. The PETHEMA/HOVON group have reported lower CR rates in 72 CD56^+^ patients compared to those 579 CD56^−^ patients \[[@B38-cancers-12-01444]\]. We reasoned the differences observed in the studies might be derived from the number of enrolled cases. Thus, we reanalyzed the 530 patients from both the APL97 and APL204 studies, which gave similar results to those for the APL204 study. In the PETHEMA/HOVON group, patients with CD56^+^ APL also reported poorer ECOG PS scores and lower albumin levels compared with our patients \[[@B38-cancers-12-01444]\]. The characteristics of patients enrolled in the study or undergoing the antileukemic regimen adopted in both studies might explain these differences.

Our study demonstrated that overexpression of CD56 was correlated with inferior RFS and higher CIR. CD56 was found to be an independent adverse prognostic factor for RFS by multivariate analysis. However, the direct or indirect molecular mechanisms to explain why CD56 expression in APL is associated with poorer prognosis are not well understood. Sobas et al., compared the five-year outcome with their previous study. CIR went up from 22% to 33% in CD56^+^ patients, but was unchanged in CD56^−^ patients. Relapse was more frequently observed in CD56^+^ patients compared to CD56^−^ ones in a long-term observation. In our study, however, late relapse three or more years after randomization did not occur in CD56^+^ patients, and thereafter, both CIR curves plateaued in parallel. The discrepancies might result from differences in patient background and variations in therapies.

In this study, CD56 expression was determined to be one of the prognostic factors in APL patients, especially those whose initial WBC counts were more than 3.0 × 10^9^/L. This observation might explain why the prognosis of patients with lower initial WBC counts was improved by ATRA plus chemotherapy \[[@B20-cancers-12-01444]\]. Moreover, tamibarotene maintenance also improved prognosis \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. Additional research is needed to ascertain the underlying reason for the poorer prognosis of CD56^+^ APL patients with higher initial WBC counts. A recent PETHEMA-LPA2012 study, which includes intensified consolidation for CD56+ group, will suggest the benefit of modification on the regimen with ATRA and chemotherapy.

The extramedullary relapse rate did not increase in our 530 patients enrolled in the APL97 and APL204 studies, while the PETHEMA/HOVON group and PETHEMA/HOVON/PALG/GATLA group have reported a higher risk of extramedullary relapse in their analysis of 651 and 956 patients, respectively \[[@B38-cancers-12-01444]\]. This difference might be because our studies included prophylactic intrathecal injection after recovery from consolidation therapy.

In this study, overexpression of CD56 was not correlated to OS. The relapsed patients received tamibarotene, ATO and/or gemutuzumab ozogamicin as well as stem cell transplantation \[[@B21-cancers-12-01444],[@B22-cancers-12-01444]\]. The reason why RFS and CIR were inferior in CD56^+^APL but not OS might be explained by the efficacy of salvage therapy with these drugs after recurrence of APL.

We think that CD56 is a next important prognostic factor to initial leukocyte count and maintenance in the treatment with ATRA and chemotherapy. It might be more important than other characteristics of APL cells, including secondary chromosomal abnormality, FLT3 mutations, multidrug resistant related factors, and BCR3 *PML-RARA* isoform. The clinical usage of CD56 expression in APL might be more important, if we assess quantitative change of CD56 over time by an advanced multicolor flow cytometry. Recently, in many institutes, we have evaluated clinical outcome of APL with the product of *PML-RARA*. However, we might need to redefine the role of multicolor flow cytometry during and after the treatment of APL as well as that adopted in the treatment of acute lymphoblastic leukemia.

Although this study has mainly focused on the clinical significance of CD56 in APL patients treated with ATRA plus chemotherapy regimen, we have also the results of treatment with ATO. Lou Y et al. \[[@B43-cancers-12-01444]\] reported that overexpression of CD56 is a potentially unfavorable prognostic factor in 184 newly diagnosed APL patients treated with ATO-based frontline therapy. Recent studies suggest more successful outcomes can be achieved by using a combination of ATRA and ATO in patients with APL, especially for low- and intermediate-risk groups \[[@B44-cancers-12-01444],[@B45-cancers-12-01444],[@B46-cancers-12-01444],[@B47-cancers-12-01444],[@B48-cancers-12-01444]\]. However, the clinical impact of CD56 was not clearly determined in these studies. The combination of ATRA and ATO could change the previous prognostic factors, including CD56, especially in the low-risk group. However, this combination therapy might have less impact in the high-risk APL group or for patients with recurrent disease. Accordingly, it is still important to determine prognostic factors such as overexpression of CD56 in APL patients, especially those with higher initial WBC counts.

5. Conclusions {#sec5-cancers-12-01444}
==============

CD56 has been continuously an independent unfavorable prognostic factor for RFS in APL patients treated with ATRA and chemotherapy followed by maintenance therapy.
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![Scheme of the APL204 study. AraC, cytarabine; ATRA, all-*trans* retinoic acid; DNR, daunorubicin; IDA, idarubicin; MIT, mitoxantrone; MTX, methotrexate; PSL, prednisolone; IT, intrathecal injection; CR, complete remission; RFS, relapse-free survival.](cancers-12-01444-g001){#cancers-12-01444-f001}

![A CONSORT diagram before and after random assignment of the APL204 study. Numbers in parentheses refer to the numbers of patients. ATRA, all-*trans* retinoic acid; DNR, daunorubicin; IDA, idarubicin; MIT, mitoxantrone; AraC, cytarabine; CR, complete remission.](cancers-12-01444-g002){#cancers-12-01444-f002}

![Long-term Kaplan--Meier curves of OS (**A**), EFS (**B**), RFS (**C**) and CIR (**D**) according to CD56 expression. EFS, RFS and CIR were inferior in CD56^+^ APL (*p* = 0.007, *p* = 0.005, *p* = 0.004, respectively) than CD56^−^ APL, while OS was not significantly different between the two groups (*p* = 0.069).](cancers-12-01444-g003){#cancers-12-01444-f003}

![RFS and CIR according to CD56 expression and initial leukocyte count. RFS (**A**) and CIR (**B**) patients with an initial leukocyte count of ≥3.0 × 10^9^/L (*n* = 81) were significantly different between CD56^+^ and CD56^−^ patients (*p* = 0.028 and *p* = 0.036, respectively). However, CD56^+^ and CD56^−^ patients (**C** and **D**, respectively) with an initial leukocyte count of \<3.0 × 10^9^/L (*n* = 174) showed no significant difference (*p* = 0.164 and *p* = 0.101, respectively).](cancers-12-01444-g004){#cancers-12-01444-f004}

cancers-12-01444-t001_Table 1

###### 

Demographics and Clinical Characteristics.

  Characteristic                                      Before Induction (*n* = 344)   Randomly Assigned for Maintenance Therapy   *p*-Value         
  --------------------------------------------------- ------------------------------ ------------------------------------------- ----------------- -------
  Age (years)                                                                        0.597                                                         
   Median (range)                                     48 (15--70)                    48 (15--70)                                 46 (16--69)       
  Sex                                                                                0.758                                                         
   Male/Female                                        183/161                        70/65                                       72/62             
  Performance status                                                                 0.858                                                         
   0/1/2/3                                            188/126/19/11                  72/50/8/5                                   78/43/8/5         
  Leukocyte count (×10^9^/L)                          0.841                                                                                        
   Median (range)                                     1.4 (0.1--127)                 1.3 (0.2--111)                              1.4 (0.2--88.5)   
  APL cell count (×10^9^/L)                                                                                                      0.502             
   Median (range)                                     0.3 (0--109)                   0.2 (0--09)                                 0.4 (0--87)       
  Platelet count (×10^9^/L)                                                          0.343                                                         
   Median (range)                                     31 (1--470)                    28 (2--208)                                 32 (1--470)       
  Sanz's risk category                                                               0.939                                                         
   Low                                                117                            47                                          44                
   Intermediate                                       157                            62                                          64                
   High                                               70                             26                                          26                
  Fibrinogen level (mg/dL)                                                                                                       0.578             
   Median (range)                                     144 (8--810)                   147 (27--593)                               137 (8--496)      
  FDP                                                                                                                                              0.784
   Median (range)                                     50.3 (0--800)                  53.7 (2.5--800)                             51.4 (0--576.5)   
  DIC score                                                                                                                                        0.946
   0--2                                               37                             14                                          15                
   3--9                                               241                            93                                          97                
   Undetermined ^†^                                   66                             28                                          22                
  FAB subtype                                                                                                                                      0.434
   M3/M3v                                             323/21                         126/9                                       128/6             
  Induction therapy group                                                            0.984                                                         
   A/B/C/D                                            112/48/70/114                  47/18/26/44                                 45/20/26/43       
  Additional Chromosome change other than t (15;17)                                  0.453                                                         
   None                                               225                            93                                          88                
   Present                                            111                            39                                          45                
   Undetermined \*                                    8                              3                                           1                 

FAB indicates French-American-British classification; ATRA indicates all-trans retinoic acid. \* undetermined either because of insufficient sample or non-dividing cells; ^†^ undetermined because of insufficient sample.

cancers-12-01444-t002_Table 2

###### 

Risk factors for CR.

  Clinical Features                                   Cases Achieving CR   Cases Who did not Achieve CR   *p*-Value
  --------------------------------------------------- -------------------- ------------------------------ -----------
  **Total**                                           319                  25                             
  Age (years)                                                                                             0.283
   15--59                                             258                  18                             
   60--70                                             61                   7                              
  Sex                                                                                                     0.124
   Male/Female                                        166/153              17/8                           
  FAB subtype                                                                                             0.201
   M3/M3v                                             301/18               22/3                           
  Leukocyte count (×10^9^/L)                                                                              0.011
   \<3.0                                              220                  11                             
   ≥3.0                                               99                   14                             
                                                                                                          0.044
   \<10.0                                             258                  16                             
   ≥10.0                                              61                   9                              
  Platelet count (×10^9^/L)                                                                               0.244
   \<40.0                                             192                  18                             
   ≥40.0                                              127                  7                              
  Sanz's risk category                                                                                    0.130
   Low                                                110                  7                              
   Intermediate                                       148                  9                              
   High                                               61                   9                              
  Performance status                                                                                      0.397
   0/1/2/3                                            178/113/18/10        10/13/1/1                      
  CD34                                                                                                    0.417
   \<10%                                              225                  18                             
   ≥10%                                               79                   4                              
  CD56                                                                                                    0.212
   \<10%                                              263                  17                             
   ≥10%                                               40                   5                              
  Additional Chromosome change other than t (15;17)                        0.351                          
   None                                               211                  14                             
   Present                                            101                  10                             
  Induction therapy                                                                                       0.066
   A/B/C/D                                            109/45/61/104        3/3/9/10                       

Categorical data were compared using χ2-test and Fisher's exact test for categorical variables. FAB indicates French-American-British classification.
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###### 

(**a**) Univariate analyses for RFS. (**b**) Multivariate analyses for RFS.

  --------------------------------------------------- -------------------- -------------------- ------------ ------------ ---------------
  **(a)**                                                                                                                 
  **Clinical Features**                               **No. of Cases**     **Median (Range)**   **HR**       **95% CI**   ***p*-Value**
  Age (years)                                                                                                             
   15--59 vs. 60--70                                  221 vs. 48           46 (15--70)          0.62         0.21--1.78   0.373
  Sex                                                                                                                     
   Male vs. Female                                    141 vs. 128                               0.73         0.36--1.47   0.376
  Leukocyte count (×10^9^/L)                                                                                              
   \<3.0 vs. ≥3.0                                     184 vs. 85           1.3 (0.2--111)       2.72         1.36--5.45   0.003
   \<10.0 vs. ≥10.0                                   217 vs. 52           3.39                 1.67--6.87   \<0.001      
  Platelet (×10^9^/L)                                                                                                     
   \<40 vs. ≥40                                       164 vs. 105          30 (1--470)          0.77         0.37--1.59   0.477
  Sanz's risk category                                                                                                    
   Low, Intermediate, and High                        52, 126, and 91                                                     0.001
  Performance status                                                                                                      
   0, 1, 2, and 3                                     149, 94, 16 and 10                                                  0.302
  CD34-positive blast                                                                                                     
   \<10% vs. ≥10%                                     191 vs. 65           3 (0--91)            2.13         1.02--4.45   0.040
  CD56-positive blast                                                                                                     
   \<10% vs. ≥10%                                     221 vs. 34           2 (0--99)            3.04         1.34--6.90   0.005
  Additional Chromosome change other than t (15;17)                                                                       
   None vs. Presence                                  181 vs. 84                                1.09         0.53--2.26   0.821
  Induction Therapy                                                                                                       
   A, B, C, and D                                     92, 38, 52 and 87                                                   0.005
  Maintenance Therapy                                                                                                     
   ATRA vs. Tamibarotene                              135 vs. 134                               0.44         0.21--0.93   0.027
  **(b)**                                                                                                                 
  **Clinical Features**                               **No. of Cases**     **Median (Range)**   **HR**       **95% CI**   ***p*-Value**
  Leukocyte count (×10^9^/L)                                                                                              
   \<10.0 vs. ≥10.0                                   204 vs. 51           1.4 (0.2--111)       3.55         1.68--7.50   0.001
  CD56-positive blast                                                                                                     
   \<10% vs. ≥10%                                     221 vs. 34           2 (0--99)            3.19         1.40--7.27   0.006
  Maintenance Therapy                                                                                                     
   ATRA vs. Tamibarotene                              125 vs. 130                               0.41         0.19--0.91   0.028
  --------------------------------------------------- -------------------- -------------------- ------------ ------------ ---------------

\(a\) Statistical analyses were done by log-rank test. (b) Statistical analyses were done by Cox-proportional-hazards-model.
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###### 

CD phenotypes and clinical outcome.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  CD\     No. of Cases   OS (%)   *p*-Value   EFS (%)   *p*-Value   No. of Cases   RFS (%)   *p*-Value    CIR (%)   *p*-Value                         
  No.                                                                                                                                                 
  ------- -------------- -------- ----------- --------- ----------- -------------- --------- ------------ --------- ----------- ------- ------ ------ -------
  CD2     193 vs. 107    90.5     81.9        0.084     84.3        72.7           0.030     153 vs. 80   92.2      83.8        0.053   6.7    16.6   0.019

  CD4     223 vs. 42     87.2     97.6        0.116     78.7        95.2           0.029     170 vs. 37   87.6      94.6        0.204   12.1   2.7    0.094

  CD5     246 vs. 11     88.4     100.0       0.231     80.3        90.0           0.366     192 vs. 10   87.5      90.0        0.847   11.7   11.1   0.932

  CD7     299 vs. 15     88.4     80.0        0.094     81.8        66.7           0.033     236 vs. 10   89.8      80.0        0.372   10.0   10.0   0.979

  CD8     243 vs. 10     88.6     100.0       0.259     80.9        88.9           0.445     187 vs. 9    88.8      88.9        0.970   10.4   12.5   0.873

  CD11b   95 vs. 17      86.9     76.5        0.216     83.1        76.5           0.467     74 vs. 11    93.2      100.0       0.377   6.76   0.0    0.372

  CD14    301 vs. 20     88.2     90.0        0.319     80.5        85.0           0.615     239 vs. 14   89.1      85.7        0.741   10.7   7.1    0.689

  CD15    67 vs. 22      87.9     77.3        0.190     82.0        77.3           0.543     55 vs. 15    90.9      100.0       0.263   9.1    0.0    0.258

  CD19    284 vs. 34     87.7     88.2        0.756     80.9        79.0           0.615     224 vs. 24   88.8      91.7        0.646   10.4   9.1    0.751

  CD20    244 vs. 9      89.1     100.0       0.292     81.3        88.9           0.528     189 vs. 8    88.4      87.5        0.941   10.8   12.5   0.858

  CD34    243 vs. 83     89.4     89.1        0.158     82.2        75.5           0.172     191 vs. 65   91.1      81.5        0.040   8.5    17.5   0.056

  CD56    280 vs. 45     89.4     78.9        0.069     83.1        66.1           0.007     221 vs. 34   91.0      76.5        0.005   8.1    23.5   0.004

  DR      245 vs. 72     87.9     88.8        0.732     80.2        81.8           0.937     191 vs. 57   89.9      87.0        0.850   6.8    5.3    0.997
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

OS, overall survival; EFS, event-free survival; RFS, relapse-free survival; CIR, cumulative incidence of relapse; DR, HLA-DR.
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###### 

Clinical feature of CD56^+^ and CD56^−^ patients.

  Characteristic                                      CD56-Positive       CD56-Negative    *p*-Value      
  --------------------------------------------------- ------------------- ---------------- ----------- -- -------
  Age (years)                                                                                             0.903
   Median (range)                                     45 (20--69)         48 (15--70)                     
  Sex                                                                     0.068                           
   Male/Female                                        18/27               153/127                         
  Performance status                                                                                      0.363
   0/1/2/3                                            21/21/3/0           154/102/14/10                   
  Leukocyte count (× 10^9^/L)                                                                             0.304
   Median (range)                                     1.7 (0.4--27)       1.3 (0.1--111)                  
  APL cell count (× 10^9^/L)                                                                              0.543
   Median (range)                                     0.7 (0--96.5)       0.2 (0--109)                    
  Platelet count (× 10^9^/L)                                                                              0.569
   Median (range)                                     33 (3--160)         30 (1--237)                     
  Sanz's risk category                                                                                    0.939
   Low                                                11                  93                              
   Intermediate                                       21                  132                             
   High                                               13                  55                              
  Fibrinogen level (mg/dL)                                                                                0.478
   Median (range)                                     166 (45--545)       139 (8--810)                    
  FDP                                                                                                     0.522
   Median (range)                                     51.2 (7.5--255.5)   52.5 (0--800)                   
  DIC score                                                                                               0.717
   0--2                                               5                   28                              
   3--9                                               30                  203                             
   Undetermined ^†^                                   10                  49                              
  Morphology                                                                                              0.172
   M3/M3v                                             40/5                264/16                          
  Induction therapy group                                                                                 0.897
   A/B/C/D                                            13/6/11/15          90/40/55/95                     
  Additional Chromosome change other than t (15;17)                       0.923                           
   None                                               30                  184                             
   Present                                            15                  89                              
   Undetermined \*                                    0                   7                               

FAB indicates French-American-British classification; ATRA indicates all-*trans* retinoic acid. \* undetermined because of insufficient sample or non-dividing cells; ^†^ undetermined because of insufficient sample.
